Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, received approval from Health Canada for Yesintek™ and Yesintek™ I.V., biosimilars to Stelara® (ustekinumab). This approval holds a major milestone in Biocon's global expansion strategy. Read full news here: https://www.coherentmarketinsights.com/news/biocon-biologics-has-received-approval-from-health-canada-1735 https://www.coherentmarketinsights.com/news/biocon-biologics-has-received-approval-from-health-canada-1735